NCT06904014View on ClinicalTrials.gov

Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 25, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2029

Conditions
HCC
Interventions
PROCEDURE

HAIC

FOLFOX-hepatic artery infusion

DRUG

Sintilimab

200mg, ivgtt, D1, Q3W

DRUG

Lenvatinib

8 mg，qd，D1-D21,Q3W

PROCEDURE

surgery

surgery

Trial Locations (1)

Unknown

RECRUITING

Shandong Cancer Hospital and Institute, Jinan

All Listed Sponsors
lead

Lei ZHAO

OTHER